BeEAM conditioning with bendamustine-replacing BCNU before autologous transplantation is safe and effective in lymphoma patients

Stefanie Gilli(University Hospital of Bern), Thomas Pabst(University Hospital of Bern), Thilo Zander(Luzerner Kantonsspital), Urban Novak(University of Bern), Thomas Egger(Solothurner Spitäler), Kurt Leibundgut(Swiss Red Cross), Gabriela M. Baerlocher(Terry Fox Research Institute), Behrouz Mansouri Taleghani(University of Bern), Daniel Betticher, Yara Banz(Beth Israel Deaconess Medical Center), Daniel Rauch(Washington University in St. Louis)
Annals of Hematology
December 24, 2016
10.1007/s00277-016-2900-y
Cited by 42

Related Papers

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
Mutations in <i>TERT,</i> the Gene for Telomerase Reverse Transcriptase, in Aplastic Anemia
|New England Journal of Medicine|2005|717
Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)
|Leukemia|2012|417
Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial
|The Lancet|2015|392
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
|Leukemia|2017|339